BR112018067784A2 - regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias - Google Patents

regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias

Info

Publication number
BR112018067784A2
BR112018067784A2 BR112018067784A BR112018067784A BR112018067784A2 BR 112018067784 A2 BR112018067784 A2 BR 112018067784A2 BR 112018067784 A BR112018067784 A BR 112018067784A BR 112018067784 A BR112018067784 A BR 112018067784A BR 112018067784 A2 BR112018067784 A2 BR 112018067784A2
Authority
BR
Brazil
Prior art keywords
treatment
dosage regimen
inflammatory conditions
acute exacerbations
exacerbations
Prior art date
Application number
BR112018067784A
Other languages
English (en)
Portuguese (pt)
Inventor
Orford Colin
Farrell Colm
Clarke Cyril
Parkin Jacqueline
De Buck Stefan
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of BR112018067784A2 publication Critical patent/BR112018067784A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018067784A 2016-03-08 2016-03-08 regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias BR112018067784A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050635 WO2017153701A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Publications (1)

Publication Number Publication Date
BR112018067784A2 true BR112018067784A2 (pt) 2019-01-15

Family

ID=55646778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067784A BR112018067784A2 (pt) 2016-03-08 2016-03-08 regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias

Country Status (9)

Country Link
US (1) US10617674B2 (enExample)
JP (1) JP6741773B2 (enExample)
KR (1) KR20180119597A (enExample)
AU (1) AU2016397046B2 (enExample)
BR (1) BR112018067784A2 (enExample)
CA (1) CA3016368A1 (enExample)
MX (1) MX389563B (enExample)
RU (1) RU2709509C1 (enExample)
WO (1) WO2017153701A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385717B (es) * 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
JP7280627B2 (ja) * 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
RU2381219C2 (ru) * 2003-06-26 2010-02-10 Новартис Аг ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) * 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
US20090270350A1 (en) * 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
LT2827860T (lt) * 2012-03-20 2016-12-12 Mereo Biopharma 1 Limited Pirazolo darinio panaudojimas stiprių lėtinės obstrukcinės plaučių ligos paūmėjimų gydymui

Also Published As

Publication number Publication date
JP2019507785A (ja) 2019-03-22
MX2018010781A (es) 2018-11-09
RU2709509C1 (ru) 2019-12-18
US10617674B2 (en) 2020-04-14
WO2017153701A1 (en) 2017-09-14
JP6741773B2 (ja) 2020-08-19
MX389563B (es) 2025-03-20
AU2016397046A1 (en) 2018-09-06
AU2016397046B2 (en) 2022-05-12
US20190091203A1 (en) 2019-03-28
CA3016368A1 (en) 2017-09-14
KR20180119597A (ko) 2018-11-02

Similar Documents

Publication Publication Date Title
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
MX2017009449A (es) Inhibidor jak.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
UY35972A (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
SV2016005313A (es) Derivados de carboxamida
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
MX379245B (es) Compuesto de tres ciclos y aplicaciones del mismo
MX384724B (es) Regímenes de dosificación de melflufen para cáncer.
BR112018067784A2 (pt) regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias
BR112018067454A2 (pt) regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica
DK4058148T3 (da) Doseringsregime for anti-bcma-midler
BR112017004552A2 (pt) composições farmacêuticas
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
CL2017000026A1 (es) Formas de dosificación farmacéutica
MX378376B (es) Composicion farmaceutica para el tratamiento de la micosis.
EA201692531A1 (ru) Способы лечения инфекций
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
CR20160591A (es) Metodos para tratar infecciones

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]